ArticleVirology journal2010
Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy.
Article in Virology journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- An open-source multi-semantic annotation dataset and automated recognition tool for viral carcinogenesis factors.Database : the journal of biological databases and curation · 2025Article
- Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.Nature communications · 2025Article
- Activated B lymphocytes and tumor cell lysate as an effective cellular cancer vaccine.Cancer immunology, immunotherapy : CII · 2021Article
- The red blood cell as a novel regulator of human B-cell activation.Immunology · 2021Article
- Overview of Cellular Immunotherapies within Transfusion Medicine for the Treatment of Malignant Diseases.International journal of molecular sciences · 2021Review
- B cell dysfunction in chronic hepatitis B virus infection.Liver research (Beijing, China) · 2021Review
- DNA aptamer-based rolling circle amplification product as a novel immunological adjuvant.Scientific reports · 2020Article
- Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study.BMC veterinary research · 2020Article
- The Multiple Functions of B Cells in Chronic HBV Infection.Frontiers in immunology · 2020Review
- B Cell-Based Cancer Immunotherapy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019Article
- CD40-activated B cells induce anti-tumor immunity in vivo.Oncotarget · 2017Article
- Efficient generation of antigen-specific CTLs by the BAFF-activated human B Lymphocytes as APCs: a novel approach for immunotherapy.Oncotarget · 2016Article
- Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients.Cellular & molecular immunology · 2015Article
- Overexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infection.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2012Article
- Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.International reviews of immunology · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to clarify whether soluble CD40 ligand (sCD40L) activated B cells may be loaded with HBcAg18-27 peptide and served as antigen-producing cells (APCs) to induce HBV-specific cytolytic T lymphocytes (CTLs).
resultsHuman B cells could be cultured in the presence of sCD40L up to 54 days, and the proportion of B cells in the S phase increased from 0% to 8.34% in the culture. The expression of CD80, CD86, major histocompatibility complex (MHC) classes I and II molecules on the sCD40L-activated B cell was significantly increased after long-time culture. Cytometry and fluorescence microscopy showed that more than 98% sCD40L-activated B cells were loaded by the HBcAg peptide. Furthermore, the peptide-pulsed activated B cells could induce HBcAg18-27 specific CTLs.
conclusionsOur results demonstrate that sCD40L-activated B cells may function as APCs and induce HBV-specific CTLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.